Objectives: Recently, open-set speech recognition performance has been observed with electric stimulation of the brainstem in some nontumor (NT) patients. These outcomes require that we reevaluate the criteria for patient selection and the rationale for expanding the application for the auditory brainstem implant (ABI) to NT adult patients with profound hearing loss. This study presents results from up to 10 years in adults, with analysis based on cause.

Materials And Methods: In our Department, from April 1997 to September 2007, ABIs have been implanted in 112 patients (83 adults and 29 children) with tumor (T) and NT disorders. Of the 112 patients, 15 have previously had a cochlear implant elsewhere with no sound detection. This article presents speech recognition results from the 80 patients (32 neurofibromatosis type 2 and 48 NT) who had achieved at least 1-year follow-up. The retrosigmoid approach was used in all NT patients, and the retrosigmoid-transmeatal approach was used in all T patients.

Results: All patients had a functioning implantation, and no complications were observed during the operation, activation, or long-term use of the ABI. At the most recent follow-up, NT adults scored from 10 to 100% in open-set speech perception tests (average, 59%), and T patients scored from 5 to 31% (average, 10%). The differences between these results are statistically significant (p = 0.0007). The best performance was observed in patients who lost their nerve VIII from head trauma or severe ossification. Lowest performance (although still highly beneficial to the patient) was observed in patients with neurologic disorders, neuropathy, and cochlear malformations.

Conclusion: Our experience clearly indicates that the ABI is an effective tool for hearing rehabilitation in patients with profound hearing loss who cannot be fitted with cochlear implants.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MAO.0b013e3181a864f2DOI Listing

Publication Analysis

Top Keywords

patients
11
auditory brainstem
8
brainstem implant
8
open-set speech
8
speech recognition
8
performance observed
8
patients profound
8
profound hearing
8
hearing loss
8
112 patients
8

Similar Publications

The Rey Auditory Verbal Learning Test (RAVLT) is a classic test used to assess episodic verbal memory in research and clinical practice. We aimed to adapt the RAVLT materials into Russian, provide performance norms across the adult lifespan for the Russian adaptation, and develop a mobile application for automated RAVLT administration across languages. We created three psycholinguistically matched alternative versions of the RAVLT materials in Russian and incorporated them into a new tablet application.

View Article and Find Full Text PDF

Idiopathic non-mast cell angioedema: Treatment insights from global experts.

Allergy Asthma Proc

January 2025

From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.

Idiopathic non-mast cell angioedema (INMA) is a rare disease typified by recurrent attacks of cutaneous and subcutaneous swelling. Every attack carries the potential for severe morbidity and, in the case of laryngeal involvement, mortality. Whereas therapies approved for hereditary angioedema (HAE) have been used in the care of patients with INMA, little is known with regard to their efficacy for the treatment of this disease.

View Article and Find Full Text PDF

Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan.

Allergy Asthma Proc

January 2025

Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.

Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.

View Article and Find Full Text PDF

Appraisal of the evidence linking hereditary α-tryptasemia with mast cell disorders, hypermobility and dysautonomia.

Allergy Asthma Proc

January 2025

From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.

Since its first description more than a decade ago, our understanding of the clinical impact of hereditary alpha-tryptasemia has continued to evolve. First considered to be a genetic disorder with a subset of patients having a syndromic presentation composed of connective tissue abnormalities, symptoms of autonomic dysfunction, and findings of mast cell activation, we now know that hereditary alpha-tryptasemia is a common genetic trait and modifier of mast cell-mediated reactions. More recent studies have shown some previously held associations with congenital hypermobility and postural orthostatic tachycardia syndrome (POTS) to be lacking, and illuminated previously unappreciated associations with clonal and nonclonal mast cell disorders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!